切除对异柠檬酸脱氢酶1突变的世界卫生组织二级星形细胞瘤恶性进展后生存的影响
这项回顾性研究分析了56例既往治疗过的IDH1突变WHO二级星形细胞瘤恶性进展后接受肿瘤切除的患者,评估手术切除和辅助治疗对病程的影响。恶性进展后中位生存期为33个月(95%CI 20-46),中位总生存期为123个月(95%CI 77-170)。全切除、术后KPS≥80、辅助放化疗和既往放疗与恶性进展后生存显著相关。
要点
- 56例IDH1突变WHO二级星形细胞瘤恶性进展后切除患者中,18例(32.1%)实现强化组织完全切除。
- 恶性进展后中位生存期33个月(95%CI 20-46),中位总生存期123个月(95%CI 77-170)。
- 全切除、术后KPS≥80、辅助放化疗及既往放疗与恶性进展后生存显著相关。
核心结论
- 临床状况良好、既往治疗过的低级别胶质瘤恶性进展患者应接受积极治疗,包括再次切除。
研究设计与样本
- 回顾性研究,纳入56例既往治疗过的IDH1突变WHO二级星形细胞瘤恶性进展后接受肿瘤切除的患者。
- 采用Kaplan-Meier估计和log-rank检验分析恶性进展后生存、总生存及预后因素。
主要发现
- 恶性转化时中位年龄44岁,中位KPS评分90。
- 18例(32.1%)患者实现强化组织完全切除。
- 再次切除后中位生存期33个月(95%CI 20-46),中位总生存期123个月(95%CI 77-170)。
- 全切除、术后KPS≥80、辅助放化疗及既往放疗与恶性进展后生存显著相关。
临床怎么用
- 作者认为,临床状况良好、既往治疗过的低级别胶质瘤恶性进展患者应接受积极治疗,包括再次切除。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the impact of surgical resection and adjuvant treatment on the course of patients after malignant progression of previously treated isocitrate dehydrogenase 1 (IDH1)-mutated World Health Organization (WHO) grade II astrocytoma. METHODS: This retrospective study explored 56 patients undergoing tumor resection for malignant progression after previously treated IDH1-mutated WHO grade II astrocytoma. We analyzed survival after malignant progression, analyzed overall survival (OS), and identified prognostic factors using Kaplan-Meier estimates and log-rank test. RESULTS: By the time of malignant transformation, median age was 44 years, and median Karnofsky Performance Status (KPS) score was 90. Complete resection of contrast-enhancing tissue was achieved in 18 (32.1%) patients. Median survival after re-resection was 33 months (95% confidence interval [CI], 20-46); median OS was 123 months (95% CI, 77-170). Gross total tumor resection, postoperative KPS score ≥80, adjuvant radiochemotherapy, and prior radiotherapy significantly correlated with post-malignant progression survival. CONCLUSIONS: Patients in good clinical condition with malignant progression of previously treated low-grade gliomas should receive aggressive treatment, including re-resection.
引用
- Grau SJ, Hampl JA, Kohl AC, et al. Impact of Resection on Survival of Isocitrate Dehydrogenase 1-Mutated World Health Organization Grade II Astrocytoma After Malignant Progression. World Neurosurg. 2017. PMID: 28377251. doi:10.1016/j.wneu.2017.03.123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。